| *Sponsored
Breaking News Again: Low Float Nasdaq Idea (TCBP) Provides Key Acquisition Strategy Update
December 31st Greetings, Friend!
TC Biopharm (Nasdaq: TCBP) is back on my watchlist early Tuesday.
In case you are unaware, this is a low float idea as MarketWatch is reporting TCBP to have fewer than 600k outstanding shares.
That means that volatility potential could be explosive.
It's also important when you recognize the company just dropped huge news. Take a look: TCBP Provides Update on Acquisition Strategy and Current Targets
EDINBURGH, Scotland, Dec. 31, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T-cell therapies for cancer and other indications, today announced it has advanced negotiations with both of its previously aforementioned acquisition candidates.
This past spring TCBP announced the execution of non-binding letters of intent as part of its M&A strategy aimed at expanding its therapeutic platform. The Company continues to pursue its expansion strategy via acquisition, specifically in new indications and new cell therapy modalities.
TCBP will be focusing its acquisition efforts on two main areas; Natural Kill cell technologies and CAR-related technologies. The Company intends to move forward with near-term acquisition opportunities in the NK space, reviewing several new opportunities in the allogeneic NK space as well as the CAR-NK space. This would expand the Company's efforts into autoimmune disease as well as additional opp's in solid tumors and combination therapies using both TCB008 and an allogeneic NK cell in combination.
Additionally, the Company is pursuing new opp's in the novel CAR space. TCB008 is an ideal candidate to be modified with new CAR technologies further to enhance its efficacy in solid tumors and other cancers. Expanding TCB008 into a CAR-modified cell increases the use case and economies of scale for the therapeutic and furthers the use of our manufacturing site, where we have room for expansion.
"TC BioPharm is encouraged by the progress that we have made during these discussions with our current acquisition targets," said Bryan Kobel, Chief Executive Officer. "We are pursuing companies that have developed proprietary approaches to their specific areas of treatment and would significantly enhance TCBP's treatment platform while meshing with our current offerings. Management is currently negotiating deal terms in good faith, and I believe the process is progressing to mutually beneficial outcomes. We hope to have additional updates soon as we remain committed to establishing ourselves as a leader in novel oncology treatments."
Read the full article here.
Take a look at my previous notes on (Nasdaq: TCBP) below and consider it for your radar today. -----
Wow. Catch what happened Friday?
My latest alert went off in a major way after it exploded from a previous night's after hours close of $4.55 to a new 52-week high of $9.40 for an approx. surge of 106%!
Heck. It even erupted in pre-market to a high of $10.78 (approx. 136% from the previous after hours close).
That said, I’m now excited to introduce you to TC BioPharm (Nasdaq: TCBP), a clinical-stage biopharma company revolutionizing the field of immunotherapy.
Here’s a quick look at why (Nasdaq: TCBP) is making itself known to the top of my watchlist to close out the year:
#1. Breakthrough Gamma-Delta T-Cell Therapy: At the core of TC BioPharm’s mission is TCB008, the first gamma-delta T-cell therapy to reach Phase II clinical trials for acute myeloid leukemia (AML). AML is one of the most challenging cancers to treat, yet TCB008 has demonstrated significant cytotoxic effects against AML cells in early studies—all while maintaining a remarkable safety profile.
#2. AI-Driven Innovation: In partnership with Carnegie Mellon University, TC BioPharm is integrating artificial intelligence into its donor screening processes. This advanced approach not only enhances precision but also ensures scalability for their allogeneic cell therapies.
#3. A Diverse, Expanding Pipeline: Beyond oncology, TC BioPharm is advancing therapies targeting fungal infections and viral diseases. This strategic diversification broadens their market potential and positions them to address urgent global health challenges.
#4. Momentum in Clinical Trials: The company’s ACHIEVE trial is progressing rapidly, with positive safety data, expanded clinical sites, and scalable manufacturing processes that reduce costs and boost accessibility.
#5. A Low Float: With MarketWatch suggesting fewer than 600k shares outstanding, this could become a volatile situation in moments.
With its cutting-edge science, strategic partnerships, and commitment to innovation, TC BioPharm (Nasdaq: TCBP) is poised to disrupt the biopharmacuetical landscape.
Consider getting TC BioPharm (Nasdaq: TCBP) on your radar now. I'll be in touch with updates as soon as they are available.
Talk again soon.
All the best, Dane James Editor Market Pulse Today
Sources: TCBP Website. TCBP Presentation.
(Remember: St-ock Prices Could Be Significantly Lower Now From The Original Dates I Provided.)
MarketPulseToday.com (“MarketPulseToday” or “MPT” ) is owned by Thousand Sun Media LLC, a limited liability company. Data is provided from third-party sources and MarketPulseToday ("MPT") is not responsible for its accuracy. Make sure to always do your own research and due diligence on any day and swing profile I bring to your attention. We do not provide personalized fin-ancial advice, are not finan-cial advisors, and our opinions are not suitable for all in-vest-ors.
Pursuant to an agreement between Thousand Sun Media LLC and TD Media LLC, Thousand Sun Media LLC has been hired by TD Media LLC for a period beginning on 12/29/2024 and ending on 12/31/2024 to publicly disseminate information about (TCBP:US) via digital communications. Under this agreement, Thousand Sun Media LLC has been paid five thousand USD (“Funds”) to disseminate information about (TCBP:US) via digital communications. These Funds were part of the funds that TD Media, LLC received from a third party who does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices.
Neither Thousand Sun Media LLC, TD Media LLC and their member own shares of (TCBP:US).
Please see important disclosure information here: https://marketpulsetoday.com/disclosure/tcbp/
The single member of Thousand Sun Media LLC is also the single member of TD Media LLC.
Pursuant to an agreement between TD Media LLC and Awareness Consulting Network LLC, TD Media LLC has been hired for a period beginning on 12/29/2024 and ending on 12/31/2024 to publicly disseminate information about (TCBP:US) via digital communications. To date, including under the previously described agreement, TD Media LLC has been paid thirty-two thousand five hundred USD (“Funds”) for (TCBP:US). These Funds were part of the funds that TD Media LLC received from a third party who did not receive the funds from the issuer and does not own stock in the issuer but the reader should assume that the clients of the third party own shares in the issuer that they will liquidate at or near the time you receive this communication, which has the potential to hurt share prices.
Please see important disclosure information here: https://lifewatermedia.com/disclosure/tcbp/ | 
No comments:
Post a Comment